INTRODUCTION 41
first line options for both treatment and prophylaxis of filamentous fungal infections [1, 2] . 48
Although these newer triazoles have a broader spectrum of activity compared to 49 fluconazole, they exhibit complex pharmacokinetics, including a propensity for drug-drug 50 interactions (DDI) with co-administered drugs [3] . All mold-active triazoles are inhibitors of one 51 or more phase 1 (cytochrome P-450) biotransformation enzymes and may also be inhibitors or 52 substrates of phase 2 biotransformation enzymes or transporter proteins such as P-glycoprotein 53
[4]. Mold-active triazoles may alter the drug absorption, distribution, excretion and metabolism of 54 co-administered agents such as benzodiazepines, anxiolytics, dihydropyridine calcium channel 55 blockers, sulfonylureas, calcineurin inhibitors, prednisone, or anticoagulants [3] . Mold-active 56 triazoles are also associated with QTc prolongation, so use should be cautioned with other 57 agents having similar effects [5] . 58
The definition of DDI varies across literature. Some studies define DDI as the 59 concomitant use of interacting drugs, while others define DDI based on clinical evidence of 60 interactions that are confirmed by either laboratory tests or by symptoms. In this paper, we use 61 the DDI term to describe the concomitant use of interacting drugs. DDI account for 3-5% of 62 preventable in-hospital adverse drug reactions and are an important cause of emergency room 63 and hospital visits [6] . DDI are associated with significant clinical consequences and higher 64 resource use and costs [7, 8] . DDI are common among patients taking multiple medications with 65 an estimated prevalence ranging from 60.0% to 70.3% among hospitalized patients and are 66 index hospitalization. Among patients with multiple eligible hospitalizations, a random 115 encounter was selected. 116
Analyses 117
A DDI event was considered to have occurred if patients used at least one drug reported 118 to interact with the index triazole during the index hospitalization, and there was at least a one-119 day overlap between the index triazole and the interacting drug. Only dispensed drugs were 120 considered in the analysis (i.e. prn only or prescribed but not dispensed drugs were excluded). 121
The half-lives of mold-active triazoles range from 6 hours (voriconazole) to 35 hours 122 (posaconazole), [3] thus at least a one-day overlap of drug use was required in the current study 123 to allow a window of opportunity for interaction. At least one-day overlap of drug use to define 124 DDI has been commonly used within the literature, [15] [7] and was used as the primary 125 analysis in the current study. As sensitivity analysis, overlaps of drug use for at least 2 and 3 126 days to define DDI were explored. 127
The prevalence and frequency of DDI events during the index hospitalization were 128 summarized and reported for all patients and by index triazole. Prevalence of DDI was defined 129 as the proportion of hospitalizations with any DDI events that occurred during the index 130 hospitalization. Frequency of DDI events were defined as the total number of DDI events of a 131 unique pair of the triazole and its interacting drug that occurred in the index hospitalization. 132
Prevalence and frequency of DDI events were further summarized by the severity of all DDI 133 events (contraindicated, major, and moderate) observed during the index hospitalizations. 134
Patient characteristics including demographic, treatment, and hospital characteristics 135 were described for all patients and stratified by DDI and non-DDI cohorts. Disease conditions 136 based on both the primary and secondary diagnosis ICD-9 codes were summarized. The top 5 137 most commonly observed IFI based on ICD-9 diagnosis codes or microbiology lab tests were 138 also reported. Differences between DDI and non-DDI cohorts in these characteristics were 139 compared using Chi-square tests for categorical variables and Wilcoxon-rank-sum tests for 140 continuous variables. 141
In addition, the 25 most frequently used interacting drugs for each triazole were 142 summarized. For each interacting drug, frequency was measured as the total number of hospital 143 admissions with the presence of the interacting drug and the interacting triazole. Rate was 144 defined as the frequency divided by the total number of hospitalizations with DDI for each 145
triazole. 146

Subgroup analysis 147
The overall patient population that met the sample selection criteria described above 148 was further selected into subgroups of patients who we hypothesized to have a higher risk for 149 DDI and to be more vulnerable to the detrimental effects of DDI. These subgroups were critically 150 ill patients or multimorbid patients who often require several concomitant medications leading to 151 an increased risk of DDI. The following subgroups were identified using ICD-9 diagnosis codes, 152 procedure codes, GPI codes, and caresetting IDs: renal failure, hematologic malignancies, 153 diabetes, neutropenia, hospitalization involving intensive care unit (ICU), corticosteroid use, 154 severe sepsis, transplantation (lung, liver, and kidney), chemotherapy, liver disease (moderate 155 or severe), and allogeneic hematopoietic stem cell transplantation (HSCT) or bone marrow 156 transplantation (BMT). DDI prevalence and frequency were reported for all patients in each 157 subgroup overall and stratified by DDI severity. 158
RESULTS
159
Sample Selection 160
A total of 6,962 hospital admissions with mold-active triazole drug use were included in 161 this study (Figure 1) . Voriconazole was the most frequently used triazole (n=4,751), followed by 162 itraconazole (n=1,794), then posaconazole (n=417). 163
The study cohort had a mean age of 57.2 (±16.9) years. About half of patients were 164 male (55.0%) and the majority of the patients were Caucasian (73.3%). Patients spent an 165 average of 7.8 days in the hospital before receiving the triazole and 74.9% of patients received 166 the triazole within 10 days of admission. The majority of patients (73.1%) initiated the index 167 triazole in oral formulation. Among patients with diagnosis information (~75%), disease 168 conditions with prevalence higher than 20% included respiratory complications, anemia, 169 hematologic malignancies, hypertension, sepsis, and acute kidney failure. Invasive fungal 170 infection (IFI) was identified in 36.6% of patients and the most common IFI were invasive 171 candidiasis infections (20.4%) and aspergillosis (11.3%) ( Table 1 ). The remaining patients might 172 be either receiving empiric or prophylactic antifungal therapy. Patient characteristics were 173 mostly similar between patients with and without DDI. Differences included patients with DDI 174 being older (57.4 vs. 55.5 years) perhaps reflecting polypharmacy as a risk, having a higher 175 proportion of Caucasian (74.0% vs. 68.2%), and initiating fluconazole sooner after hospital 176 admission than those without DDI (7.5 vs. 9.8 days). 177
DDI prevalence and frequency 178
Among the included hospitalizations, 6,101 (87.6%) had DDI. The prevalence was 87.8% 179 for voriconazole, 86.1% for itraconazole and 92.6% for posaconazole ( Figure 2a ) when DDI was 180 defined by at least one-day overlap of drug use. The mean (SD) number of DDI events per 181 admission was 3.5 (±2.4) among all admissions. The DDI frequency was relatively similar 182 among the triazoles with 3.9 (±2.4) events per admission observed in the posaconazole cohort, 183 followed by voriconazole (3.7±2.5), and then itraconazole (3.0±2.2) (Figure 2b ). The frequency 184 of contraindicated PDDI events per admission was less than one among all mold-active triazole 185 cohorts (0.3±0.6 for all hospitalizations, 0.2±0.5 for voriconazole, 0.4±0.6 for itraconazole, and 186
0.9±0.8 for posaconazole). 187
When the prevalence of all DDI events within each hospitalization was summarized by 188 severity, 26.2% of all hospitalizations had at least one contraindicated DDI, 76.3% had at least 189 one major DDI and 74.7% had at least one moderate DDI. The prevalence for contradicted, 190 major and moderate DDI was 19.5%, 81.6% and 75.0% for voriconazole, 34%, 60.7% and 75.5% 191 for itraconazole, and 67.9%, 83.0% and 67.1% for posaconazole, respectively ( Figure 2a) . 192 In the sensitivity analysis, when DDI was defined by at least two-days and three-days 193 overlap of drug use, the prevalence of any DDI among all hospitalizations changed to 80.7% 194 and 65.4%, respectively, and the prevalence of contraindicated DDI decreased to 18.4% and 195
13.4%. 196
Mold-Active Triazole Interacting Drugs 197
The most commonly used interacting drug among hospital admissions with voriconazole 198 was ondansetron, which was used in 47.6% of admissions with a voriconazole-related DDI 199 event and classified as a major DDI event based upon arrhythmia risk. The other commonly 200 observed voriconazole interacting drugs, which contributed to more than 20% of DDI events, 201
were pantoprazole (31.8%, moderate), esomeprazole (29.2%, moderate), fentanyl (28.2%, 202 major), midazolam (23.9%, moderate), and levofloxacin (21.3%, major) ( Table 2a ). The most 203 commonly observed itraconazole-interacting drugs were ondansetron (38.2%, major), 204 pantoprazole (27.0%, moderate), prednisone (23.5%, moderate), and esomeprazole (22.3%, 205 moderate) (Table 2b ). The most commonly observed posaconazole-interacting drugs were 206 ondansetron (54.9%, contraindicated), lorazepam (42.7%, moderate), promethazine (31.1%, 207 major), ciprofloxacin (29.3%, major), prochlorperazine (27.2%, major), esomeprazole (21.5%, 208 major), fentanyl (20.7%, major), and pantoprazole (20.7%, moderate) (Table 2c ). Among drugs 209 with contraindicated or major DDI with mold-active triazoles, many are widely used for treating 210 common conditions, and include warfarin (prevents heart attacks and strokes), amiodarione 211 (treats cardiac dysrhythmias), statins (i.e., simvastatin and atorvastatin, used to lower 212 cholesterol), cyclosporine (treats rheumatoid arthritis and psoriasis patients, and prevents 213 transplant rejection), and alprazolam (treats anxiety). 214
Subgroup analysis 215
Across all subgroups of patients at higher risk for DDI that were evaluated, the 216 prevalence rate of any DDI ranged from 79.7% for hospitalizations with solid organ 217 transplantation (lung, liver or kidney) to 90.6% for hospitalizations involving ICU (Table 3a) . The 218 mean number of all DDI events per admission ranged from 3.5 for hospitalizations with a 219 diagnosis of neutropenia to 5.6 for hospitalizations with allogeneic HSCT/BMT (Table 3b) . 220
221
DISCUSSION
222
DDI with triazoles poses a serious risk of adverse events including QT prolongation and 223 subsequent arrhythmia, skeletal muscle toxicity, seizures, ergotism, respiratory depression, 224 nephrotoxicity, hypoglycemia, and leukopenia [18] [19] [20] . In addition, the risk of DDI and the 225 associated adverse events are particularly challenging among critically ill and multi-morbid 226 patients who typically require several concomitant medications and are vulnerable to the clinical 227 signs and symptoms of DDI [4, 21] . Insightful case series and reviews have demonstrated the 228 clinical importance of these interactions [3, 22, 23] . This retrospective study used a large 229 electronic medical records dataset to investigate the prevalence and frequency of DDI among 230 hospital admissions involving the use of mold-active triazoles and found that more than 85% of 231 hospitalizations with mold-active triazole use had at least one DDI event. Among all 232 hospitalizations with mold-active triazole use, 26% had a DDI event with contraindicated 233 severity ( Figure 2a) and 87% had at least one DDI with major or moderate severity (data not 234 shown). Multiple DDI events per patient were common with an average of 3.5 observed DDI 235 events. The prevalence of DDI was greater than 90% in certain subgroups, such as 236 hospitalizations involving ICU and admissions for hematologic malignancies and neutropenia, 237 and the DDI frequency was greater than 5 events per admission among the subgroup with 238 admissions for allogeneic HSCT/BMT. 239
The introduction of mold-active triazole agents during the past two decades (itraconazole 240 has transformed the management of IFI [25] . Distinct from the yeast only activity of fluconazole, 242 these agents offer broad activity against both invasive candidiasis and invasive aspergillosis, 243 which were the most commonly observed IFIs in this study [2, 26] . Despite their efficacy against 244 mold infections, these triazoles are often associated with frequent DDI, due both to the long list 245 of interacting medications and the frequency of comorbid conditions associated with their use, 246 leading to polypharmacy. In this study, it was observed that patients had an average of 12 247 distinct disease conditions; the most common diagnoses included hematologic malignancies 248 and critical illnesses such as respiratory failure, acute kidney failure, and sepsis. In addition, on 249 average, each patient was prescribed 36 distinct medications during each admission. The most 250 frequently observed interacting drugs in the current study were ondansetron, pantoprazole, 251 lorazepam, esomeprazole, prednisone, and promethazine. The majority of the frequently 252 observed interacting drugs have major or moderate interactions with the triazole. The clinical 253 relevance of some of these interactions has been debated. For example, the QT-prolongation 254 linked to concomitant ondansetron can be modest. However, the effect appears dose 255 dependent and linked to intravenous use more common to those receiving chemotherapy. interactions can be dangerous especially among patients receiving chemotherapy, solid organ 272 transplantation or critically ill patients treated in the ICU [33] . This study provides real-world 273 evidence indicating that the majority of patients treated with mold-active triazoles during 274 hospitalizations have DDI risk. Given that these patients often have multiple conditions requiring 275 many treatments, full avoidance of DDI might not be entirely feasible; however, greater 276 awareness of DDI could reduce the potential for clinically relevant interactions. 277
The high prevalence of DDI observed in this study was generally consistent with the 278 literature; however, rates were even higher in this contemporary study. Egger et al. reported a 279 rate of DDI of 60% among consecutive hospital admissions with at least two prescriptions 280 regardless of the underlying disease conditions and drugs used [13] . Yu et al. found a DDI rate 281 of 70.3% in hospitalizations in which fluconazole, itraconazole or ketoconazole were used [14] . 282
Almost all patients in that study used fluconazole (94.5%), and only a limited number of 283 admissions used itraconazole (n=212) and ketoconazole (n=68), and there were no patients 284 using voriconazole or posaconazole. 285
The current study is subject to several limitations. First, this study was conducted in the 286
Cerner electronic medical record database, which might limit the generalizability of the findings 287 to all the hospitals in the US. All the hospitalizations included for the DDI analysis were from 288 urban hospitals with the majority of hospitals affiliated with a teaching facility and having more 289 than 300 beds, which might not be generalizable to all the hospitals in the US. Second, this 290 study has not evaluated how many of the DDI events would eventually lead to an adverse event. 291
Due to the limitations of electronic medical records data, it is not possible to evaluate the clinical 292 outcomes and consequences of DDI events. Future research is warranted to address this 293 question. Third, the study has not evaluated whether physicians would adjust treatments, such 294 as changes in medications and reducing dosage. This is particularly relevant for drugs that are 295 commonly administered with therapeutic drug monitoring, such as warfarin and calcineurin 296 inhibitors. Lastly, the current study used at least one-day overlap of drug use to define DDI in 297 the primary analysis, which might cause an overestimation of the prevalence given the half-life 298 of drugs might be less than 1 day and dispending records instead of administration records 299 were used for the evaluation. 300
CONCLUSION 301
DDI is highly prevalent among hospitalized patients receiving mold-active triazoles, and 302 there are often multiple DDI events per admission. Efforts are needed to increase the 303 awareness of DDI, and to decrease the risk of DDI among mold-active triazole users via 304 electronic medical record tools and antifungal stewardship. 305
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